72 related articles for article (PubMed ID: 12107968)
1. [Anticancer chemotherapy containing cisplatin in patients with lung cancer and kidney function].
Wiela-Hojeńska A; Passowicz-Muszyńska E; Orzechowska-Juzwenko K; Jankowska R; Hurkacz M; Unolt J; Weryńska B; Gołecki M; Dyła T
Pol Arch Med Wewn; 2002 Feb; 107(2):135-40. PubMed ID: 12107968
[TBL] [Abstract][Full Text] [Related]
2. Supplemental fosfomycin and/or steroids that reduce cisplatin-induced nephrotoxicity.
Umeki S; Watanabe M; Yagi S; Soejima R
Am J Med Sci; 1988 Jan; 295(1):6-10. PubMed ID: 2827472
[TBL] [Abstract][Full Text] [Related]
3. Urinastatin (Kunitz-type proteinase inhibitor) reducing cisplatin nephrotoxicity.
Umeki S; Tsukiyama K; Okimoto N; Soejima R
Am J Med Sci; 1989 Oct; 298(4):221-6. PubMed ID: 2552802
[TBL] [Abstract][Full Text] [Related]
4. Early measurement of urinary N-acetyl-β-glucosaminidase helps predict severe hyponatremia associated with cisplatin-containing chemotherapy.
Arakawa Y; Tamura M; Sakuyama T; Aiba K; Eto S; Yuda M; Tanaka Y; Matsumoto A; Nishikawa K
J Infect Chemother; 2015 Jul; 21(7):502-6. PubMed ID: 25851853
[TBL] [Abstract][Full Text] [Related]
5. [Preventive effect of prostaglandin E1 on cisplatin-induced nephrotoxicity].
Takayama K; Nakanishi Y; Takano K; Harada T; Inoue K; Osaki S; Minami T; Hara N
Gan To Kagaku Ryoho; 1999 Mar; 26(4):503-8. PubMed ID: 10097747
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of methods for evaluating the nephrotoxicity of cisplatin].
Suzumori K; Yasui Y; Suzumori K; Yagami Y; Seki T
Gan To Kagaku Ryoho; 1988 Aug; 15(8):2251-6. PubMed ID: 3044273
[TBL] [Abstract][Full Text] [Related]
8. The evaluation of cisplatin effect on tubular function in children on chemotherapy.
Zareifar S; Jafari H; Geramizadeh B; Basiratnia M; Golafshan H; Cohan N; Mehravar Z; Hamidi R
Pediatr Hematol Oncol; 2013 Feb; 30(1):18-24. PubMed ID: 23163346
[TBL] [Abstract][Full Text] [Related]
9. Serial-measured versus estimated creatinine clearance in patients with non-small cell lung cancer receiving cisplatin-based chemotherapy.
Chang GC; Yang TY; Shih CM; Lin LY; Lee HS; Chiang CD
J Formos Med Assoc; 2003 Apr; 102(4):257-61. PubMed ID: 12833190
[TBL] [Abstract][Full Text] [Related]
10. [Incidence, risk factors and prevention of cisplatin-induced nephrotoxicity in patients with lung cancer].
Losonczy G; Máthé C; Müller V; Szondy K; Moldvay J
Magy Onkol; 2010 Dec; 54(4):289-96. PubMed ID: 21163759
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin nephrotoxicity and protection by silibinin.
Gaedeke J; Fels LM; Bokemeyer C; Mengs U; Stolte H; Lentzen H
Nephrol Dial Transplant; 1996 Jan; 11(1):55-62. PubMed ID: 8649653
[TBL] [Abstract][Full Text] [Related]
12. [Clinical investigation of cis-platinum nephrotoxicity in 244 cases of primary lung cancer].
Soejima A; Inoue T; Suzuki M; Waku M; Nakabayashi K; Kitamoto K; Nagasawa T
Nihon Jinzo Gakkai Shi; 1992 Jul; 34(7):801-6. PubMed ID: 1479719
[TBL] [Abstract][Full Text] [Related]
13. [Prophylactic effect of ulinastatin on cisplatin-induced renal disorders in lung cancer patients].
Horiguchi T; Kasahara J; Ogura K; Handa M; Hosoda H; Shakato A; Tachikawa S; Sato M; Suetsugu S; Umeda H
Nihon Kyobu Shikkan Gakkai Zasshi; 1992 Jan; 30(1):12-9. PubMed ID: 1625386
[TBL] [Abstract][Full Text] [Related]
14. Urine ratio of neutrophil gelatinase-associated lipocalin to creatinine as a marker for early detection of cisplatin-associated nephrotoxicity.
Shahbazi F; Sadighi S; Dashti-Khavidaki S; Shahi F; Mirzania M
Iran J Kidney Dis; 2015 Jul; 9(4):306-10. PubMed ID: 26174458
[TBL] [Abstract][Full Text] [Related]
15. Absence of effect of SLC22A2 genotype on cisplatin-induced nephrotoxicity in oesophageal cancer patients receiving cisplatin and 5-fluorouracil: report of results discordant with those of earlier studies.
Hinai Y; Motoyama S; Niioka T; Miura M
J Clin Pharm Ther; 2013 Dec; 38(6):498-503. PubMed ID: 24102360
[TBL] [Abstract][Full Text] [Related]
16. The ameliorative effect of cysteine prodrug L-2-oxothiazolidine-4-carboxylic acid on cisplatin-induced nephrotoxicity in rats.
Ali BH; Al Moundhri MS; Tag Eldin M; Nemmar A; Tanira MO
Fundam Clin Pharmacol; 2007 Oct; 21(5):547-53. PubMed ID: 17868208
[TBL] [Abstract][Full Text] [Related]
17. [The pharmacokinetics of cisplatin and its influence on renal functions based on different infusion methods].
Takahashi A; Takagi M; Hishida H; Saji E; Takagi N; Amano H; Ogura Y
Gan To Kagaku Ryoho; 1987 Oct; 14(10):2944-50. PubMed ID: 3116947
[TBL] [Abstract][Full Text] [Related]
18. [NAG (N-acetyl-beta-D-glucosaminidase)--a sensitive marker for disorders of kidney function].
Skrezek C; Bertermann H; Schulz FP; König B
Urologe A; 1990 Jan; 29(1):27-31. PubMed ID: 2316078
[TBL] [Abstract][Full Text] [Related]
19. [Studies on serum and urinary alpha 1-microglobulin levels as parameter of the renal function--renal function observed after CDDP administration].
Ujiie T; Maruta H; Ito N
Hinyokika Kiyo; 1988 May; 34(5):790-6. PubMed ID: 2459938
[TBL] [Abstract][Full Text] [Related]
20. [Effects of fractionated low dose Cisplatin on renal functions of patients with gastric carcinoma].
Li Y; Shen L; Li J; Jin ML
Ai Zheng; 2007 Dec; 26(12):1354-6. PubMed ID: 18076800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
